Instructions
Please read this page carefully. You will need to scroll down this page and ensure that you have read the learning objectives, accreditation information, and potential conflicts of interest disclosures for the authoring faculty. Please check the box to agree to the terms of understanding and click the "Start Module" button on the bottom of the page to begin your learning activity.

Learning Objectives
After successful completion of this continuing medical education activity, participants should be better able to:

• State the appropriate course of action for patients with stage II-III NSCLC with positive margins versus negative margins following surgical resection
• Explain recommended first-line adjuvant therapy for stage II-III NSCLC
• Discuss the major controversy relating to the sequence of treatment modalities for patients with stage IIIA disease
• Compare and contrast the appropriate use of bevacizumab in the various types and subtypes of NSCLC
• Detail the baseline prognostic variables that predict survival in NSCLC
• Recommend the most appropriate management strategies for metastatic squamous cell carcinoma
• Discuss the advantages of cisplatin over best supportive care in patients with advanced, incurable disease
• Outline adjuvant treatment options for patients who cannot tolerate cisplatin-based regimens
• Compare and contrast concurrent chemotherapy/radiation therapy and sequential chemotherapy/radiation therapy and state the advantages and disadvantages of each

Accreditation
This learning activity has expired however you may still review module content.

Target Audience
This learning activity is intended for a broad audience of healthcare practitioners, including medical oncologists, primary care physicians, family physicians, specialists, nurse practitioners, and physician assistants.

Disclosure Statements
To view the Disclosure Statements, please click here.